In its latest SEC filing, Generali Asset Management SPA SGR reported a 51.6% increase in its position in Illumina, acquiring an additional 7,574 shares during Q3 and bringing its total stake to 22,249 shares, representing a market value of approximately 2.11 million. This marks one of the largest quarter-over-quarter percentage increases among reported institutional investors, underscoring Generali’s growing confidence in Illumina’s long-term growth trajectory in the genomics and life sciences markets.

Several high-profile funds have also tweaked their Illumina allocations in recent quarters. WCM Investment Management added roughly 5.9% to its holdings in Q2, lifting its total to over 4.4 million shares. Loomis Sayles increased its position by 1.9%, while AQR Capital Management executed a substantial 55.3% boost—purchasing more than one million additional shares. Geode Capital and UBS Asset Management each modestly raised their stakes, with UBS’s first-quarter increase exceeding 50%, reflecting a broader institutional belief in Illumina’s resilient revenue streams and innovation pipeline.

Illumina’s Q3 earnings report delivered EPS of 1.34, surpassing consensus by 18 cents, on revenue of 1.08 billion—edging out analyst expectations by 10 million. Net margin improved to 16.4%, while return on equity climbed to 29.2%. Year-over-year revenue growth was modest at 0.4%, but management’s guidance for fiscal 2025 EPS in the 4.65 to 4.75 range signals a full-year growth target that analysts view as achievable given ongoing demand for next-generation sequencing platforms and consumables in clinical and research applications.

Insider activity shows mixed signals: Director Scott Gottlieb added 500 shares in early November at an average cost of 122.13 per share, while VP Scott Davies sold 323 shares in mid-December at an average price of 136.09, trimming his holding by 1.77%. On the sell-side, five firms have issued buy ratings versus fourteen holds and two sells. Price objectives range from 109.00 up to 142.00, yielding an average target near 118.31. Recent upgrades from Evercore ISI and JPMorgan highlight optimism about Illumina’s product rollout and margin expansion potential through 2025.